Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press8610.17650/2220-3478-2014-0-4-27-31ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯEXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGIONОПЫТ ПРИМЕНЕНИЯ БЕВАЦИЗУМАБА У БОЛЬНЫХ НЕОПЕРАБЕЛЬНЫМ КОЛОРЕКТАЛЬНЫМ РАКОМ В КИРОВСКОЙ ОБЛАСТИShermanN. Z.ШерманН. З.
Russian Federation
chemotherapy@list.ruRamazanovaM. S.РамазановаМ. С.
Russian Federation
chemotherapy@list.ruGopachenkoYe. N.ГопаченкоЕ. Н.
Russian Federation
chemotherapy@list.ruDepartment of Chemotherapy, Kirov Regional Clinical Oncology DispensaryОтделение химиотерапии КОГБУЗ «Кировский областной клинический онкологический диспансер»Department of Oncology, Kirov State Medical Academy, Ministry of Health of RussiaКафедра онкологии ГБОУ ВПО «Кировская государственная медицинская академия» Минздрава России281220143427310103201501032015Copyright ©; 2014, Sherman N.Z., Ramazanova M.S., Gopachenko Y.N.Copyright ©; 2014, Шерман Н.З., Рамазанова М.С., Гопаченко Е.Н.2014Sherman N.Z., Ramazanova M.S., Gopachenko Y.N.Шерман Н.З., Рамазанова М.С., Гопаченко Е.Н.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/86

Purpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov regional clinical oncology dispensary.

Materials and methods. The study was conducted in Kirov regional clinical oncology dispensary from 2008 until 2014. 35 patients treated with combined first line therapy including bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab were retrospectively evaluated. Overall response was evaluated using RECIST ver. 1.1 criteria. Long term outcomes – progression free and overall survival were evaluated. Treatment safety was evaluated using NCI CTCAE.

Results. There were no complete remissions in second line bevacizumab treatment, partial remissions were detected for 4 (22.2 %) patients, stable disease for 14 (77.8 %). Median progression free survival in both groups was comparable 9.1 and 10.4 months respectively. Patients treated with bevacizumab in first and second lines of treatment had 8.2 months survival benefit (p > 0.05).

Conclusions. Combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with bevacizumab improves overall survival on 8.2 months in comparison with patients who stopped bevacizumab treatment after first disease progression.

metastatic colorectal cancerbevacizumabfirst-line treatmentmaintenance therapysecond-line treatmentметастатический колоректальный ракбевацизумабпервая линия терапииподдерживающая терапиявторая линия терапии1. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 250 с.Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 250 с.2. Raja F.A., Hook J.M., Ledermann J.A. Biomarkers in the development of antiangiogenic therapies for ovarian cancer. Cancer Treat Rev 2012;38:662–72.Raja F.A., Hook J.M., Ledermann J.A. Biomarkers in the development of antiangiogenic therapies for ovarian cancer. Cancer Treat Rev 2012;38:662–72.3. Moghaddam M.S., Amini A., Morris D.L., Pourgholami M.H. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012;31:143–62.Moghaddam M.S., Amini A., Morris D.L., Pourgholami M.H. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012;31:143–62.4. Wu H.C., Li P.C. Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. J Cancer Molec 2008;4:17–22.Wu H.C., Li P.C. Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. J Cancer Molec 2008;4:17–22.5. Giantonio B.J. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat Rev Clin Oncol 2009;6: 311–2.Giantonio B.J. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat Rev Clin Oncol 2009;6: 311–2.6. Melnyk O., Zimmerman M., Kim K.J., Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a preclinical model. J Urol 1999;161:960–3.Melnyk O., Zimmerman M., Kim K.J., Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a preclinical model. J Urol 1999;161:960–3.7. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249–56.Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249–56.8. Klement G., Baruchel S., Rak J. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15–24.Klement G., Baruchel S., Rak J. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15–24.9. Klement G., Huang P., Mayer B. et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrugresistant human breast cancer xenografts. Clin Cancer Res 2002;8:221–32.Klement G., Huang P., Mayer B. et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrugresistant human breast cancer xenografts. Clin Cancer Res 2002;8:221–32.10. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335–42.Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335–42.11. Saltz L.B., Clarke S., Dнaz-Rubio E. et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008 Jun;26(12):2013–9.Saltz L.B., Clarke S., Dнaz-Rubio E. et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008 Jun;26(12):2013–9.12. Tebbutt N.C., Wilson K., Gebski V.J. et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010;28(19):3191–8.Tebbutt N.C., Wilson K., Gebski V.J. et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010;28(19):3191–8.13. Cunningham D., Lang I., Marcuello E. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomized phase 3 trial. Lancet Oncol 2013;14(11): 1077–85.Cunningham D., Lang I., Marcuello E. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomized phase 3 trial. Lancet Oncol 2013;14(11): 1077–85.14. Dнaz-Rubio E., Gуmez-Espaсa A., Massutн B. et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012;17(1):15–25.Dнaz-Rubio E., Gуmez-Espaсa A., Massutн B. et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012;17(1):15–25.15. Koopman M., Simkens L., MayA.M. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32(suppl 3; abstr LBA388).Koopman M., Simkens L., MayA.M. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32(suppl 3; abstr LBA388).16. Koopman M., Simkens L., MayA.M. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s(suppl; abstr 3504).Koopman M., Simkens L., MayA.M. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s(suppl; abstr 3504).17. Kozloff M., Yood M.U., Berlin J. et al. Clinical outcomes associated with bevacizumab containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862–70.Kozloff M., Yood M.U., Berlin J. et al. Clinical outcomes associated with bevacizumab containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862–70.18. Bendell J.C., Bekaii-Saab T.S., Cohn A.L. et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17:1486–95.Bendell J.C., Bekaii-Saab T.S., Cohn A.L. et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17:1486–95.19. Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29–37.Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29–37.20. Grothey A., Sugrue M.M., Purdie D.M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008: 26:5326–34.Grothey A., Sugrue M.M., Purdie D.M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008: 26:5326–34.21. Cohn A.L., Bekaii-Saab T., Bendell J.C. et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010;28:15s (suppl; abstr 3596).Cohn A.L., Bekaii-Saab T., Bendell J.C. et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010;28:15s (suppl; abstr 3596).